

MINOCA

Myocardial infarction with non-obstructive coronary arteries

O. Hlinomaz



ICRC, FN u sv. Anny, Brno



MINOCA

Definice a incidence

- Syndrom s různými příčinami
- Klinická evidence MI při normálních nebo téměř normálních koronárních arteriích (stenóza <50%)
- Kolem 10% všech AKS

Table 1. Morality Outcomes Between MINOCA and MICAD Patients

	MINOCA % (n)	MICAD % (n)	p value
In-hospital	0.3% (1)	2.1% (58)	<0.05
1 month	0.3% (1)	2.5% (69)	<0.05
12 months	0.9% (3)	3.7% (102)	<0.05

p value from Fisher's exact test

Coronary angiography Database of South Australia (CADOSA) Registry
1.2012-12.2013
3145 pac. koronaro pro AIM
347 (11%) MINOCA

Table 2. Return Hospital Visits for Cardiovascular Cause Between MINOCA and MICAD Patients

	MINOCA % (n)	MICAD % (n)	OR 95% CI	p value
1 month	8.9% (30)	9.4% (257)	0.89 (0.59-1.34)	>0.05
12 months	14% (48)	18% (494)	0.88 (0.49-0.98)	<0.05

MINOCA pac. ↓ celkovou mortalitu
ale stejnou frekvenci návštěv v nem. jako
MICAD pac.

Dg. kritéria


1. AIM kritéria

- Pozitivní ukazatelé nekrozy myokardu
- Klinické známky IM
 - Ischemické symptomy
 - Nové změny ST úseků nebo nový BLTR
 - Vznik patol. Q kmitů
 - Nová ztráta viabilního myokardu nebo porucha hybnosti dle zobrazovacích metod
 - Intrakoronární trombus

Dg. kritéria

2. Koronární arterie bez významné stenózy při angiografii (<50%)
 - Normální koronární aa. ($\leq 30\%$)
 - Mírná koronární ateroskleróza (31-49%)


3. Nejasná příčina akutního stavu v době angiografie
 - Další vyšetření nutností s cílem zjistit příčinu



Příčiny

1. Ruptura atero plátu
2. Spasmus koronární aa.
3. Koronární (tromb)embolismus
4. Koronární disekce
5. Takotsubo kardiomyopatie
6. Myokarditis


1. Ruptura atero plátu



09:16 stenokardie




Heparin 5000j i.v.
 Kardegic 500mg i.v., Efient 6 tbl.

10:00 bez potíží






M, 65 let

Nejasná culprit léze



Po implantaci DES



XA16/6

Fr: 1

Left Coronary 15 fps

FN U SV. ANNY

2.3.1980

36Y F

0172-605/16

7-3-2016

10:34:56

Ž, 36 let

27.3 LAO


0.5 CAU

79.6 kV

898.0 mA

Velikost pixelu: 0.342 mm

W: 256 L: 128




XA/3/3

FN U SV. ANNY

Fr: 1

Left Coronary 15 fps



2.3.1980

36Y F

0172-605/16

7-3-2016

10:34:56



34.2 RAO

10.4 CRA

76.1 kV

883.0 mA

Velikost pixelu: 0.258 mm

W: 256 L: 128




XA777

Fr: 1

Left Coronary 15 fps

FN U SV ANNY



2.3.1980

36Y F

0172-605/16

7-3-2016

10:34:56



32.2 RAO

2.8 CRA

73.5 kV



760.0 mA

Velikost pixelu: 0.342 mm

W: 256 L: 122



Transmurální IM PS




2. Koronární spasmus

Vasospastic Angina pectoris

reproducibilita sy
>90% redukce lumen
přechodné STE

reproducibilita sy
není >90% redukce lumen
ischemické EKG změny




acetylcholin i.v., ergonovine i.v.

Provokační testy na koronární spasmus

Authors	Year	Ergonovine maleate	Acetylcholine	Route
Bertrand et al.	1982	Methergine* 400 mg	N/A	iv
Waters et al.	1983	12.5–400 mg	N/A	iv
Yasue et al.	1986	N/A	20–100 mg (LCA); 20–50 mg (RCA)	ic
Hackett et al.	1987	6–50 mg	N/A	ic
Okumura et al.	1988	200 mg*	20–100 mg (LCA); 20–50 mg (RCA)	iv*(Erg), ic(Ach)
Harding et al.	1992	50–150 mg	N/A	iv
Song et al.	1996	25–50 mg**		iv (Echo)
Akasaka et al.	1997	100 mg (up to 200 mg)	N/A	iv
Sueda et al.	1999	40 mg (RCA); 64 mg (LCA)	20–100 mg (LCA); 20–80 mg (RCA)	ic
Takagi et al.	2003	20–60 mg (LCA); 20–60 mg (RCA)	20–100 mg (LCA); 20–50 mg (RCA)	ic
Japanese Circulation Society	2010	20–60 mg (LCA); 20–60 mg (RCA)	20–100 mg (LCA); 20–50 mg (RCA)	ic
Ong et al.	2014	N/A	Modified from Sueda	ic
Shin, Baek.et al.	2015	Same as JSC	N/A	ic


Fokální spasmus – horší prognóza



Vasospatická AP je častá ale málo dg.

Clinical Usefulness, Angiographic Characteristics, and Safety Evaluation of Intracoronary Acetylcholine Provocation Testing Among 921 Consecutive White Patients With Unobstructed Coronary Arteries

Peter Ong, MD; Anastasios Athanasiadis, MD; Gabor Borgulya, MD, MSc; Ismail Vokshi, MBBS; Rachel Bastiaenen, MBBS; Sebastian Kubik; Stephan Hill, MD; Tim Schäufele, MD; Heiko Mahrholdt, MD; Juan Carlos Kaski MD, DSc*; Udo Sechtem, MD*



Indikace provokačního testu


- podezření na vasospastickou AP (recid. klid. steno)
- AKS bez prokázané culprit léze
- nevysvětlená srdeční zástava
- nevysvětlená synkopa s předcházejícími stenokardiemi
- opakovaná klidová AP po PCI

KI: AKS, MVD, těžká deprese funkce LK


3. Koronární embolismus

26-ti letý muž, při potápěčském výcviku po vynoření z 5-ti metrů kolaps, zmatenost, pareza 3 končetin, dušnost, neklid

Hospitalizace ARK 15.4.-18.5.2004 – exitus letalis na multiorgánové srdeční selhání




Barotrauma při potápění




Koronaro 16.4.2004:
 hladkostěnné koron. aa.
 EF 25%, LVEDP 33mmHg
 difuzní porucha kinetiky
 Dg.: AIM

Vzduchová embolie




Foramen ovale patens






75-ti letý muž,
IM DS subakutní
KBLTR
Killip II







EF 35%
akineza DS

Fibroelastom v levé síni



4. Spontánní koronární disekce

Mladá žena, 32 let, 6 měsíců po porodu , NSTEMI PS




Angiograficky – ohraničená stenóza prox. RIA, na OCT intramurální hematom



Postup ???

Konzervativně ????? (32 let , mladá žena)
PCI ?????

Konzervativní postup - DAPT, Ca blokátor,
 rekonarografie za 6 týdnů - angio i OCT , plné zhojení




Žena 50 let, bolesti na hrudi, fibrilace komor při po příjezdu do nemocnice, KPR – vyšetřována intubována, ekg - BPRTw



Angiograficky : hraniční stenóza na prox. RC

OCT : intramurální hematom, suspekce ze separace medie a adveticie i na kmene ACS

Po 6 týdnech – angiograficky normální obraz, OCT- hojící se hematom rekonarografie pro opakované potíže po 2 měsících – bez recidivy



5. Takotsubo kardiomyopatie



European Journal of Heart Failure (2016) 18, 8–27
doi:10.1002/ejhf.424


REVIEW

Current state of knowledge on Takotsubo syndrome: a position statement from the task force on Takotsubo syndrome of the Heart Failure Association of the European Society of Cardiology

Alexander R. Lyon^{1,2,*}, Eduardo Bossone³, Birke Schneider⁴, Udo Sechtem⁵, Rodolfo Citro⁶, S.Richard Underwood^{1,2}, Mary N. Sheppard⁷, Gemma A. Figtree^{8,9}, Guido Parodi¹⁰, Yoshihiro J. Akashi¹¹, Frank Ruschitzka¹², Gerasimos Filippatos¹³, Alexandre Mebazaa¹⁴, and Elmir Omerovic¹⁵

Takotsubo syndrome is increasingly recognized and reported. It appears to be more common than previously recognized, but the precise incidence is not known.


Many features of TS suggest a different pathophysiological condition from atherosclerotic CAD



Summary of pathophysiological hypotheses


Vascular	Acute multivessel coronary spasm. Aborted myocardial infarction with spontaneous recanalization.
Myocardial	Acute increased ventricular afterload. Acute left ventricular outflow tract obstruction. Direct catecholamine-mediated myocardial stunning.
Vascular and myocardial	Integrated cardiovascular physiology (a cardio-circulatory syndrome).

Apikální typ




Ž, 84 let
UPV

Midventrikulární typ



M, 55 let
Ca rekta před OP

6. Myokarditis



M, 28 let


XA/6/6

I.IKAK FN U SV. ANNY, BRNO CZ



Fr: 1

Left Coro 15 fps Normal



18.3.1988

27Y M

0172-726/16

17-3-2016

12:50:19



12.6 LAO

28.8 CAU

85.3 kV

770.0 mA

Velikost pixelu: 0.342 mm

W: 1023 L: 511



XA/8/8

I.IKAK.FN U SV. ANNY, BRNO CZ

Fr: 1

Left Coro 15 fps Normal

18.3.1988

27Y M

0172-726/16

17-3-2016

12:50:19

30.4 RAO


1.4 CRA

77.6 kV

840.0 mA

Velikost pixelu: 0.342 mm

W: 1023 L: 511



Myokarditis




Late gadolinium enhancement subepikardiálně

Závěry

- MINOCA – syndrom
- pátrat po příčině: OCT, NMR, TEE, acetylcholin
- prognóza lepší než u MICAD ale horší než u zdravých
- léčba dle příčiny, často nejednoznačná

Vyšetřovací metody



Standard Method of Provocation Test: Intracoronary Ergonovine Administration

1. Control Angiography of Left and Right Coronary Arteries:

- Perform CAG in an appropriate projection that ensures the best separation of the branches of each coronary artery. After injection of ergonovine, perform CAG in the same projection again.

2. Injection of Ergonovine into the Left Coronary Artery:

- Inject 20~60 μg of ergonovine in solution in physiological saline into the LCA over a period of several minutes (about 2~5 minutes).
- Perform CAG 1~2 minutes after completion of the injection.
- In the event of an ischemic change on the ECG or chest symptom, perform CAG at the time of its onset.
- In case of a (-)ve result in the provocation test, proceed to the RCA provocation test 5 minutes later.

3. Injection of Ergonovine into the Right Coronary Artery:

- Inject 20~60 μg of ergonovine in solution in physiological saline into the RAC over a period of several minutes (about 2~5 minutes). The timing of angiography is the same as for the LCA.

4. Left and Right Coronary Angiography after administration of Nitrate:

- Administer a sufficient dose of nitrate into each coronary artery, and perform CAG while the coronary artery is maximally dilated

R. Tavella¹, S. Pasupathy¹, J. Lu², M. Arstall³, D. Chew⁴, M. Worthley¹, C. Zeitz¹, JF. Beltrame¹

(1) The University of Adelaide, Central Adelaide Local Health Network, Adelaide, Australia (2) The University of Adelaide, Adelaide, Australia

(3) The University of Adelaide, Northern Adelaide Local Health Network, Adelaide, Australia (4) Flinders University, Southern Adelaide Local Health Network, Adelaide, Australia

Background

- Myocardial infarction with non-obstructive coronary arteries (MINOCA) is increasingly recognized following acute angiography, with studies reporting a prevalence of approximately 10%.

Circulation

Systematic Review of Patients Presenting with Suspected Myocardial Infarction and Non-Obstructive Coronary Arteries (MINOCA)

- A recent meta-analysis highlights the importance of considering MINOCA a 'working diagnosis'

- The European Society of Cardiology position paper indicates large registries are needed to provide reliable estimates of the true prevalence and prognostic relevance of MINOCA.

ESC working group position paper on myocardial infarction with non-obstructive coronary arteries

Stefan Agewall¹, John F. Beltrame², Harmony R. Reynolds³, Alexander Niessner⁴, Giuseppe Foschino⁵, Alida L. P. Cabero⁶, Raffaele Di Caterina⁶, Marco Zammarò⁶, Marco Roffi⁷, Keld Kjeldsen⁸, Dan Atar¹, Juan C. Koski⁹, Udo Schramm¹⁰, and Per Tornevall¹¹, on behalf of the WG on Cardiovascular Pharmacotherapy

Aims

- To detail the 12-month prognosis of patients with MINOCA versus patients with myocardial infarction with obstructive coronary artery disease (MICAD) in relation to all-cause mortality and return hospital visits for cardiovascular diagnoses.

Methods

- All consecutive patients undergoing coronary angiography for acute myocardial infarction (AMI) in South Australian public hospitals from January 2012 to December 2013 were captured utilising the Coronary Angiogram Database of South Australia (CADOSA) Registry.

Methods

CADOSA Registry


CADOSA is a procedural registry of all public cardiac catheterisation procedures in South Australia, Australia (population = 1.8 million).

Definitions

The AMI patients were classified as MICAD or MINOCA on the basis of the presence or absence of a significant angiographic stenosis ($\geq 50\%$).

Patient Follow-up

Determined from administrative datasets.



Results

- From 3,145 patients undergoing angiography for AMI, 347 (11%) were classified as MINOCA.
- MINOCA patients were younger (59 ± 15 vs. 64 ± 13 , $p < 0.05$) and more likely to be female (60% vs. 26%, $p < 0.05$)




Figure 1: Comparison of clinical characteristics between MINOCA and MICAD. * $p < 0.01$, age adjusted

Results

- Over 12-months, the total prevalence of adverse outcomes (mortality or re-admission) in MINOCA was 19.9% compared to 26.5% in MICAD (OR 0.68, 0.51-0.91, $p < 0.05$, age adjusted).

Table 1. Mortality Outcomes Between MINOCA and MICAD Patients

	MINOCA % (n)	MICAD % (n)	p value
In-hospital	0.3% (1)	2.1% (58)	<0.05
1 month	0.3% (1)	2.5% (69)	<0.05
12 months	0.9% (3)	3.7% (102)	<0.05

p value from Fisher's exact test

Table 2. Return Hospital Visits for Cardiovascular Cause Between MINOCA and MICAD Patients

	MINOCA % (n)	MICAD % (n)	OR 95% CI	p value
1 month	8.9% (30)	9.4% (257)	0.89 (0.59-1.34)	>0.05
12 months	14% (48)	18% (494)	0.68 (0.49-0.96)	<0.05

Odds ratio presented for MINOCA patients, obtained from logistic regression and adjusted for age

Conclusion

- Although MINOCA patients have a reduced 12-month all-cause mortality compared to MICAD patients, their re-presentation to hospital is similar and warrants further attention.





Figure 1 Recommended diagnostic and therapeutic algorithm for myocardial infarction with non-obstructive coronary arteries. * Takotsubo cardiomyopathy cannot be diagnosed with certainty in the acute phase as the definition requires follow-up imaging to document recovery of left ventricular function. In the authors' experience, some patients with apparent takotsubo have unrecognized ischaemic injury or myocarditis. We therefore recommend CMR when takotsubo cardiomyopathy is suspected. ** Plaque disruption (rupture, or erosion) should be suspected and intracoronary imaging considered whenever an alternate aetiology of the clinical presentation such as myocarditis or vasospasm has not been clearly identified, particularly among those patients with evidence of atherosclerosis on the coronary angiogram. Intravascular ultrasound and intracoronary optical coherence tomography frequently show more atherosclerotic plaque than may be appreciated on angiography. They also increase sensitivity for dissection. If intracoronary imaging is to be performed, it is appropriate to carry out this imaging at the time of the acute cardiac catheterization, after diagnostic angiography. Patients should be made aware of the additional information the test can provide and the small increase in risk associated with intracoronary imaging. *** Provocative testing for coronary artery spasm has been safely performed by experienced clinical researchers in selected patients with a recent acute myocardial infarction.³⁴ However, death cases have been reported (Per Tornvall Tornberg, personal communication) and this should not be a standard procedure among the patients, particularly in the acute phase. **** Clinically suspected myocarditis (no angiographic stenosis \geq 50% plus non-ischaemic pattern on cardiac magnetic resonance imaging) by ESC Task Force criteria.³⁶ Diagnosis of certainty and aetiological diagnosis of myocarditis requires EMB (histology, immunohistology, infectious agents by PCR). AMI, acute myocardial infarction; BNP, B-type natriuretic peptide; CRP, C-reactive protein; Hb, hemoglobin; IVUS, intravascular ultrasound; LGE, late gadolinium enhancement; LV, left ventricle; MRI, magnetic resonance imaging; OCT, optical coherence tomography; SO₂, Oxygen saturation; WBC, white blood cell count.





Brain activation in patients with Takotsubo cardiomyopathy

Acute phase (day 1-4)



Chronic phase (day 28-39)

Case 1
(57/M)





^{99m}Tc SPECT



Case 1



Case 2
(44/F)



Case 3
(82/F)



Yellow: hippocampus, Red: brainstem
Green: basal ganglia, Blue: prefrontal cortex




MINOCA


Aetiologies

1. Positive remodeled unstable plaques, plaque rupture, erosion
2. Coronary spasm (epicardial or microvascular)
3. Takotsubo syndrome
4. Myocarditis
5. Thromboembolism
6. Spontaneous dissection (often obstructive disease)
7. Type 2 MI causes (often obstructive disease)



Prognosis of non obstructive CAD





Koronární spasmus

